The review, led by Madlen Hörold of the Institute of Social Medicine and Health Systems Research at Otto von Guericke University Magdeburg together with colleagues from Regensburg, Halle, Dresden and other German centers, followed the Joanna Briggs Institute methodology for scoping reviews and reported according to the PRISMA-ScR checklist. The team searched MEDLINE, the Cochrane Library, Web of Science and CINAHL for studies published between January 2015 and March 2026, using a search strategy built on the PCC framework of Population, Concept and Context. After an initial sweep that yielded 2,862 records and a second, extended search adding 1,189 more, the researchers screened titles and abstracts independently, resolved disagreements through discussion with a supervisor, and supplemented the database results with manual screening of reference lists. From 2,993 references, 21 studies made the final cut.

Those 21 studies, published between 2016 and 2026, comprised thirteen quantitative investigations, three qualitative studies, three reviews and two mixed-methods papers. Geographically, the literature is heavily skewed: nine studies came from Australia, four from the United Kingdom, and the remainder from Denmark, Poland, the Netherlands and Iran. That concentration is not accidental. Australia and New Zealand carry the world’s highest melanoma burden, with an age-standardized incidence of 37.0 per 100,000 in 2022, compared with 30.6 in Norway and 16.5 in the United States. Intriguingly, despite those high rates, the review identified no randomized controlled trials of survivorship care from Norway or the USA, a gap the authors highlight as unexpected.

Within the included literature, the researchers identified seven distinct survivorship care programs: ASICA, which stands for Achieving Integrated Self-directed Cancer Aftercare for Melanoma; Mel-Self, which incorporated the ASICA intervention; Melanoma Care; MELACARE; MELCARE; CAPABLE; and a regional pilot program in Poland’s Lower Silesian Voivodeship. To organize what these programs actually deliver, the team applied the Cancer Survivorship Care Quality Framework, a structure developed by Nekhlyudov and colleagues that distinguishes five clinical domains from several contextual ones. The analysis, conducted as a qualitative content analysis following the Elo and Kyngäs methodology with the software MAXQDA 22, mapped each program’s components onto prevention and surveillance for recurrences and new cancers; surveillance and management of physical effects; surveillance and management of psychosocial effects; surveillance and management of chronic medical conditions; and health promotion and disease prevention.

The most heavily populated domain was recurrence surveillance, addressed by twelve studies. Here the review drew on work by Silverstein and colleagues, who summarized National Comprehensive Cancer Network guidance recommending skin and lymph node examinations every three to six months for two years after treatment, then every three to twelve months for a further three years, and annually thereafter as clinically indicated. Several programs push this surveillance toward the patient and the primary care system. Kamminga and colleagues discussed low-threshold skin checks and shifting recurrence monitoring to general practitioners, while digital, tablet-based interventions described in multiple studies support total skin self-examination at home, with images and data routed to a dermatology nurse practitioner for timely clinical response. The ASICA trials in the UK exemplify this approach, pairing structured self-examination training with personalized skin maps and nurse feedback.

Physical effects of modern therapy received attention in nine studies, and this is where the immunotherapy era creates genuinely new clinical demands. Silverstein and colleagues described screening and management of acute and chronic immune-related adverse events, including cardiovascular disease, inflammatory conditions, endocrinopathy and lymphedema, stressing that any new signs or symptoms appearing after immune checkpoint inhibitor therapy must be appropriately investigated. Kamminga and colleagues, in their qualitative work with oncology providers, framed the need for uniform and patient-driven oncological follow-up as one of four core concepts of survivorship care, adaptable to individual patient circumstances. Chronic condition management, however, was the thinnest domain of all: only a single article addressed it, recommending routine follow-up visits plus bloodwork every six to twelve months to catch late immune-related effects such as endocrinopathies, and involvement of subspecialty care when chronic conditions emerge during treatment.

Psychosocial care fared considerably better, appearing in twelve of the twenty-one studies. Reported interventions ranged widely: screening for anxiety, depression, sleep disturbances and financial toxicity; assessment of fertility impact and social support systems; monitoring of melanoma-specific health-related quality of life; and education in coping with fear of cancer recurrence using metacognitive strategies such as detached mindfulness and worry postponement. The MELACARE trial in Denmark combined nurse-led follow-up with skin self-examination training and fear-of-recurrence management for early-stage patients. Telephone-based psychotherapeutic sessions appeared in the Melanoma Care program, while older trials reviewed within the literature tested spiritually focused meditation, which produced less depression and more positive affect among metastatic melanoma patients, and telephone-based peer support, which patients found an acceptable substitute for face-to-face contact. Kamminga’s team argued that psychosocial problems should at minimum be identified through short questionnaires or patient-reported outcome measures, including work-related difficulties that patients often hesitate to raise in clinic.

Beyond the five clinical domains, the review mapped contextual features of the healthcare system that determine whether programs actually function. Eighteen articles addressed communication and decision making, describing personalized information combined with practical guidance, referral guides clarifying where to seek help, short educational videos, a psychoeducational booklet titled Melanoma: Questions and Answers, and communication channels spanning phone, email, SMS and Skype. Clinical structure was another recurring theme, with nurse-led follow-up in person or by telephone, scheduled appointments with plastic surgeons, medical coordinators, and health information systems including electronic medical records and telehealth. Care coordination, emphasized in five articles, emerged as a critical ingredient: survivorship care plans to facilitate follow-up, multidisciplinary teams that reduce patient uncertainty by giving a clear overview of next steps, a fixed contact person or case manager such as a clinical nurse specialist, and fast-tracked unscheduled clinic visits when a tele-dermatologist recommends them.

The review’s verdict is nuanced. The literature collectively covers all main areas of the Cancer Survivorship Care Quality Framework, but no single program covers all domains, and most studies focused on patients with stage 0 to IIc disease, leaving survivors of advanced melanoma comparatively underrepresented. Pilot randomized trials showed their concepts were feasible and acceptable, and survivorship care appears to reduce anxiety and depression, potentially improving quality of life, but the programs demand substantial investment in human and technological resources. Two empirical gaps stand out sharply: health literacy, where only the MELCARE program offered guidance on self-management strategies and online resources, and health economics, where no included study provided cost analyses. The authors argue that with a plethora of health information available and digital health applications proliferating, promoting patients’ health literacy should be a high priority. Their findings are intended to feed directly into the participatory development of a multimodal, patient-centered survivorship care program for people living with and beyond melanoma, funded by German Cancer Aid, with further research needed to confirm the effectiveness of survivorship care plans and to establish their economic case before widespread implementation.

Subject of Research: Survivorship care programs and follow-up needs of melanoma patients

Article Title: Survivorship care for melanoma patients: a scoping review

Article References: Survivorship care for melanoma patients: a scoping review. (n.d.). https://doi.org/10.1007/s11764-026-02067-5

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02067-5

Keywords: melanoma, cancer survivorship, scoping review, immunotherapy, checkpoint inhibitors, skin self-examination, psychosocial care, health literacy, nurse-led follow-up, telehealth, recurrence surveillance, survivorship care plans

Unlike clinical depression or generalized anxiety, diabetes distress is a condition-specific phenomenon: a predictable, near-constant response to the relentless cognitive, emotional and logistical demands of keeping a failing pancreas artificially alive. Researchers have long known that this distress is common among adults with type 1 diabetes and is linked to worse self-management, poorer glycemic outcomes and reduced quality of life. What has remained murky is how that distress is actually experienced at different stages of adult life—a gap the new study set out to close by listening directly to patients rather than measuring them with questionnaires.

The research team, led by investigators at the Albert Einstein College of Medicine and Montefiore Medical Center in the Bronx, used a user-centered design approach, a methodology borrowed from product development that treats patients as genuine stakeholders rather than passive subjects. Nineteen adults with type 1 diabetes took part in six virtual workshops, each lasting about 90 minutes and facilitated by a clinical psychologist. Four sessions were devoted to young adults aged 18 to 34, whose mean age was 23.8 years, and two sessions gathered adults aged 35 to 64. The younger group was notably diverse, with nearly 43 percent identifying as Hispanic or Latino and another 43 percent as Black or African American, while the older group comprised five women recruited through a national patient advocacy council. Sessions were audio-recorded, professionally transcribed and analyzed with an inductive coding process in NVivo, with two analysts independently developing the framework and an audit trail maintained throughout to document every analytic decision.

The first and perhaps most striking finding is how much the two age groups share. Participants across the board identified competing daily priorities as a central driver of distress, alongside the financial and insurance-related friction of obtaining supplies and medications. The burden, participants stressed, was not merely economic. Navigating prior authorizations, recurring administrative hurdles and coverage disputes exacted its own emotional toll. Interpersonal strain surfaced in both groups as well—professional relationships, friendships and family dynamics all reshaped by the visibility of the disease, the sense of being misunderstood, and the exhausting need to repeatedly explain or justify diabetes-related needs. Encounters with the healthcare system emerged as another shared sore point, with participants describing feelings of judgment, frustration and a sense that their emotional well-being was treated as an afterthought to glucose metrics.

Where the groups diverged was in the temporal framing of their suffering. Young adults described distress as immediate and intrusive, a constant background presence that shaped everyday decisions and interfered with the developmental work of establishing independence and identity. Rather than a series of discrete tasks, diabetes was portrayed as an uninvited companion at work, in school and in social settings. Participants admitted to silencing alarms, delaying treatment or hiding their care during meetings to avoid disruption or unwanted attention. Technology figured prominently in this age group’s distress: device malfunctions, alarm fatigue and the sheer visibility of continuous glucose monitors and pumps contributed to feelings of stigma and of being marked as different from peers, sometimes pushing participants toward disengagement from self-care altogether.

Adults aged 35 to 64 told a strikingly different story. For them, distress was cumulative and future-oriented, shaped by decades of unbroken disease management, the accumulation of co-existing medical conditions and mounting anxieties about sustaining care into retirement. Many reflected on how their distress had evolved over the years, with self-management increasingly intertwined with family responsibilities, caregiving demands and long-term financial planning. The fear of complications and the physical wear and tear of long-standing diabetes loomed large. Clinical visits were frequently described as judgment-laden experiences—one participant compared meeting with the endocrinologist to sitting in the principal’s office—while the financial arithmetic of survival was expressed with bleak candor: the amount spent to stay alive, one participant noted, could have bought a house.

Across both groups, participants consistently distinguished diabetes distress from depression and anxiety, framing it instead as an expected reaction to a complex, lifelong condition. One participant captured the pervasiveness of the phenomenon by observing that almost everything a person with type 1 diabetes goes through has the potential to cause distress, from difficulty obtaining supplies to navigating insurance requirements to accessing timely care. The cognitive load was a recurring motif: young adults spoke of working hard simply to stay alive, while older participants tallied the extra hundreds of decisions the disease forces into each day. Taken together, the narratives suggest that diabetes distress arises not from any isolated task but from the cumulative challenge of integrating relentless disease management into the competing demands of ordinary life.

The study’s findings carry direct consequences for how psychological interventions are built. Core strategies—emotional validation, cognitive restructuring and problem-solving—appear broadly relevant across age groups, but the researchers argue that content and emphasis should be tuned to life-stage-specific stressors. The workshops directly informed the refinement of the Reduce intervention, a cognitive-behavioral program being developed within two ongoing randomized controlled trials. For young adults, that means addressing technology fatigue, competing priorities and identity-related concerns; for the older group, it means emphasizing cumulative burden, caregiving responsibilities and long-term planning. The authors also flag implications for routine clinical screening, suggesting that standard questionnaires may underestimate distress when they focus narrowly on emotional symptoms while ignoring contextual stressors such as cost, caregiving or technology burden. Brief, open-ended questions in routine encounters, paired with clinician training in empathetic, non-punitive communication, could improve detection of distress that is situational, cumulative or anticipatory in nature.

There are limits worth noting. The sample was small, workshop sizes shrank below their intended scale because of scheduling constraints, and every participant in the 35-to-64 group was female, which may constrain transferability to men of the same age. No validated distress instrument was administered, so severity cannot be benchmarked against established clinical thresholds, and recruitment from clinics and advocacy organizations likely captured people already engaged in care. Older adults aged 65 and beyond were outside the study’s scope and remain an important frontier, as aging with type 1 diabetes introduces clinical and psychosocial challenges of its own. Future work, the authors suggest, should examine distress longitudinally, stratify analyses by age and disease duration, and include more racially, ethnically and socioeconomically diverse populations, given well-documented disparities in outcomes and access.

What the study ultimately delivers is a conceptual upgrade: diabetes distress, long treated as a static psychological state, emerges instead as a dynamic, developmental and profoundly systemic experience—one shaped as much by insurance bureaucracy, algorithmic alarms and the architecture of clinical encounters as by individual coping. For a condition that demands vigilance every waking hour, recognizing that the meaning of that vigilance changes across a lifetime may be the first step toward support that people actually find worth using.

Subject of Research: Life stage differences in diabetes distress among adults with type 1 diabetes explored through user-centered design workshops

Article Title: Understanding Diabetes Distress Across Adulthood in Type 1 Diabetes: A User‐Centered Design Study

Article References: Rayden, R., Crespo‐Ramos, G., Finnan, M., Hoogendoorn, C., Farchione, T., & Gonzalez, J. S. (2026). Understanding Diabetes Distress Across Adulthood in Type 1 Diabetes: A User‐Centered Design Study. Endocrinology, Diabetes & Metabolism, 9(5), Article e70331. https://doi.org/10.1002/edm2.70331

Image Credits: AI Generated

DOI: 10.1002/edm2.70331

Keywords: type 1 diabetes, diabetes distress, user-centered design, mental health, young adults, aging, cognitive-behavioral intervention, healthcare burden, insurance barriers, diabetes technology, qualitative research, psychosocial care